Combined EZH2 and HDAC inhibitors kill CRPC cells and trigger regression of CRPCs in vivo.(A) Box plot displaying z score values of EZH2 mRNA expression in normal prostate, primary prostate adenocarcinoma, and metastatic prostate cancer tumors. Data obtained from Grasso and colleagues [45] (S1 Da...
more
Combined EZH2 and HDAC inhibitors kill CRPC cells and trigger regression of CRPCs in vivo.(A) Box plot displaying z score values of EZH2 mRNA expression in normal prostate, primary prostate adenocarcinoma, and metastatic prostate cancer tumors. Data obtained from Grasso and colleagues [45] (S1 Data). (B) Bar graph illustrating the cytotoxic effects of EZH2 and HDAC inhibitors. Three human prostate cell lines (PC3, C42B, and LNCaP) and one mouse cell line (PT-09) were treated with DMSO, 5 μM GSK126 (EZH2i), 2 μM vorinostat (HDACi), or both agents combined as described. Manual cell counting was performed on day 0 and on day 4 after combined treatment. Graphs (left) show log2 FC in cell number on day 4 compared to day 0. Immunoblots (right) confirm target inhibition (S1 Data). (C) Synergy plot using Gaddum’s noninteraction model (HSA) for PC3 cells treated with EZH2i (GSK126) and/or HDACi (vorinostat). Plot is representative of 3 replicates. (D) Graph depicting percentage of caspase 3/7+ (apoptotic) cells over time using Incucyte live cell imaging (S1 Data). (E) Bar graph illustrating the cytotoxic effects of panobinostat and GSK126. PC3 cells were treated with DMSO, 5 μM GSK126 (EZH2i), 20 nM Panobinostat (Pano), or a combination of the 2 inhibitors. Log2 FC was calculated as in Fig 1B (left) (S1 Data). (F) Bar graph illustrating the cytotoxic effects of combined EED/HDAC inhibitors. PC3 cells were treated with DMSO, 2 μM vorinostat (HDACi), 5 μM GSK126 (EZH2i), 5 μM MAK683 (EEDi), or combined agents as denoted. Log2 FC was calculated as in Fig 1B (left) (S1 Data). Immunoblots (right) show target inhibition in each experimental group at 24 hours posttreatment. (G) Waterfall plot depicting log2 FC in tumor volume of PC3 xenografts after 18 days of treatment with EZH2i (GSK126) and/or HDACi (vorinostat). (n = 8–12 per arm) (S1 Data). (H) Tumor growth curve of PC3 xenograft from (G) over 18 days of treatment. The combination treatment arm contains only tumors that responded to the treatment so that the kinetics of regression could be visualized (n ≥ 8 tumors per arm) (S1 Data). (I) Immunohistochemistry of CC3 in PC3 xenografts after 11 days of treatment (7 days pretreatment ±EZH2i plus 4 days ±HDACi). (J) Waterfall plot depicting log2 FC in tumor volume of mouse PT-09 allografts after 18 days of treatment with EZH2i (GSK126) and/or HDACi (vorinostat). (n = 10 per arm) (S1 Data). For all subfigures, data are mean ± SD of biological independent samples, except for in vivo data, which are reported as mean ± SE. P values measured by unpaired one-tailed heteroscedastic Student t test. CC3, cleaved caspase 3; CRPC, castration-resistant prostate cancer; EZH2, enhancer of zeste homologue 2; FC, fold change; HDAC, histone deacetylase.
less